Idorsia thanks Guy Braunstein for his years of service as he retires
March 22 2024 - 2:00AM
UK Regulatory
Idorsia thanks Guy Braunstein for his years of service as he
retires
- Guy Braunstein, currently Chief Medical Officer and member of
the Idorsia Executive Committee, to retire at the end of March
2024
Allschwil, Switzerland – March 22, 2024
Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who
has served as Chief Medical Officer (CMO) since 2022 and Head of
Global Clinical Development and member of the Idorsia Executive
Committee since the creation of Idorsia will retire at the end of
March 2024. Guy will continue to support Idorsia as an advisor,
especially in the analysis and interpretation of the data coming
from the programs that he has initiated and led during his time
with the company.
Jean-Paul Clozel, MD and Chief Executive Officer of
Idorsia commented:
“Over the last 15 years, Guy has made a huge contribution to
Idorsia and to Actelion before that. As Head of Global Clinical
Development until 2022, Guy was instrumental in successfully
steering several drugs in several very different indications from
rare diseases and specialty indications, such as pulmonary arterial
hypertension, lysosomal disorders, and multiple sclerosis, to
public health issues including insomnia and hypertension, through
to approval. In his most recent role as Chief Medical Officer, Guy
was critical in unifying the company’s quality and governance
standards to ensure an uncompromisingly ethical and scientifically
rigorous approach along the lifecycle of all products in Idorsia’s
pipeline. I am very happy that we can continue to benefit from
Guy’s vast experience after his retirement since he will serve as
an advisor to Idorsia.”
Guy Braunstein, MD, PhD, and Chief Medical Officer of
Idorsia commented:
“It has been an absolute privilege to work with an outstanding team
of experts who are all dedicated to improving peoples’ lives with
innovative medicines. I believe that bringing new drugs to
prescribers and having a real impact on patients is one of the most
rewarding endeavors. Having worked as a pulmonologist practitioner
for a number of years, and joined the pharmaceutical industry in
1988, I am very proud of all that we have achieved over the past 15
years of my career at Actelion and Idorsia. I am satisfied that the
clinical development is in safe hands with Alberto Gimona and, with
the support of Antonio Olivieri, that we have all the correct
checks and balances in place to ensure appropriate and safe use of
Idorsia’s medicinal products and medical ethics in engagement with
various stakeholders. I am therefore ready to hand the reigns over
and start my retirement. I am also very happy to stay involved in
the projects that have given me such job satisfaction over the
years.”
The CMO role was created in 2022 to ensure that Idorsia’s
approach to medical governance and its policies and procedures are
globally aligned and consistent across Drug Discovery, Clinical
Development, Pharmaceutical Development and Global and Local
Medical Affairs. From April 1st, the CMO role will be
assumed by Antonio Olivieri, who will continue to lead the Global
Medical Affairs function of Idorsia, merging with Global Clinical
Development reporting into Alberto Gimona, Head of Global Clinical
Development & Medical Affairs, and member of the Idorsia
Executive Committee.
Jean-Paul continued:
“I am very pleased that with Antonio, we already have the ideal
candidate to succeed Guy from within our ranks. Antonio joined
Idorsia in 2020 and built our Global Medical Affairs function from
the ground up. In his new role as Chief Medical Officer, Antonio
will continue to ensure that we maintain our focus on ethical
excellence and communicating to the medical community about our
innovative portfolio.”
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 20-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 800 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Idorsia (LSE:0RQE)
Historical Stock Chart
From Jan 2024 to Jan 2025
